Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease

• Published in: The Korean journal of internal medicine 2007, 22(1), , pp.37-39
• Main Authors: Kim, Hyun-Sook, Park, Jae-Hyeong, Park, Seoung Ju, Park, Jong Kwan, Lee, Heung-Bum
• Format: Article
• Language: English
• Subjects: Carbolines - therapeutic use; Case Report; Exercise Tolerance - drug effects; Humans; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - etiology; Male; Middle Aged; Oxygen Consumption - drug effects; Phosphodiesterase Inhibitors - therapeutic use; Pulmonary Artery - drug effects; Pulmonary Artery - pathology; Pulmonary Disease, Chronic Obstructive - complications; Tadalafil; 내과학
• ISSN: 1226-3303; 2005-6648
• DOI: 10.3904/kjim.2007.22.1.37

Pulmonary arterial hypertension (PAH) secondary to chronic obstructive pulmonary disease (COPD) is incurable and it has an unpredictable survival rate. Two men who suffered from COPD presented with progressive dyspnea and edema, respectively. PAH, as estimated by the peak velocity of tricuspidal regurgitation, and the depressed myocardial performance index (MPI) of the right ventricle (RV) were noted on echocardiography. In addition to the baseline therapy for their depressed ventilatory function, we prescribed tadalafil 10 mg orally every other day for 2 weeks and then we doubled the dosage. They well tolerated the medication without any notable side effects. After 4 weeks of tadalafil treatment, the patients' pulmonary arterial pressure was decreased and the MPI of the RV was improved in both. The exercise capacity, as measured by the respiratory oxygen uptake, also improved from 10.9 mL/kg/min to 13.8 mL/kg/min in one patient. We report here on 2 patients with PAH secondary to COPD, and they showed notable improvement of their pulmonary hemodynamics and exercise capacity with the administration of tadalafil.